<DOC>
	<DOCNO>NCT00953979</DOCNO>
	<brief_summary>This prospective randomized control study evaluate efficacy safety kunxian capsule treat patient early ankylose spondylitis ( AS ) . The major outcome index proportion patient achieve ASAS20 response week12 , minor outcome index include ASAS50 ASAS70 , BASDAI20 , BASDAI50 BASDAI70 . The adverse event time record evaluate safety .</brief_summary>
	<brief_title>Efficacy Safety Kunxian Capsule Treatment Patients With Early Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>16 65 year old , sign informed consent ; fulfill ESSG criterion diagnosis SpA ; fulfill 1984 modified NewYork criterion AS ; BASDAI score 4 ; stop take DMARDs least 4 week ; NSAIDs dosage stable least 4 week ; Intraarticular injection cortisone within 3 month . History heart failure , multiple sclerosis , COPD , lymphoma tumor ; Accompanied fibromyalgia rheumatic disease ; Female pregnancy breast feeding ; History mental disease poor compliance . History drug abuse alcoholism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>ankylose spondylitis</keyword>
	<keyword>treatment</keyword>
	<keyword>Sulfasalazine</keyword>
	<keyword>kunxian capsule</keyword>
</DOC>